Tissue Engineered Nigrostriatal Pathway for Anatomical Tract Reconstruction in Parkinson's Disease

组织工程黑质纹状体通路用于帕金森病的解剖束重建

• 批准号: 10737098
• 负责人: Daniel Kacy Cullen
• 金额: $ 40.23万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10737098
• 关键词: Address; Adhesives; Affect; Anatomy; Animal Model; Animals; Architecture; Axon; Basal Ganglia; Behavioral; Cell Therapy; Cells; Cessation of life; Characteristics; Clinical Research; Clinical Treatment; Confocal Microscopy; Corpus striatum structure; DLG4 gene; Dendrites; Disease model; Dopamine; Dorsal; Electrophysiology (science); Ensure; Excision; Exhibits; Fiber; Forelimb; Future; GIRK2 subunit, G protein-coupled inwardly-rectifying potassium channel; Genetic; Goals; Human; Hyaluronic Acid; Hydrogels; Immunohistochemistry; Implant; In Vitro; Lesion; Limb structure; Maps; Measurement; Measures; Mediating; Medical; Methods; Modeling; Modification; Motor; Nerve Degeneration; Neural Pathways; Neurites; Neuroanatomy; Neurodegenerative Disorders; Neurons; Neurosciences; Optics; Outcome; Parkinson Disease; Pathway interactions; Patients; Pattern; Performance; Periodicity; Persons; Physiological; Population; Positron-Emission Tomography; Presynaptic Terminals; Rattus; Recovery; Regulation; Role; Scanning; Signal Transduction; Substantia nigra structure; Synapses; Synapsins; System; Techniques; Testing; Time; Tissue Engineering; Tubular formation; Visualization; biomaterial compatibility; dopaminergic neuron; human stem cells; implantation; improved; in vivo; induced pluripotent stem cell; motor deficit; motor recovery; motor symptom; multidisciplinary; neglect; nerve supply; neural; neuroimaging; neurosurgery; nigrostriatal pathway; pars compacta; pharmacologic; postsynaptic; preclinical study; preservation; presynaptic; rabies viral tracing; receptor function; reconstruction; reinnervation; repaired; response; restoration; stem cell differentiation; stem cells; tau Proteins; treatment strategy; uptake

ABSTRACT Parkinson’s disease (PD) is a progressive neurodegenerative disease that affects 10 million people worldwide. Its motor symptoms result from selective degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to a loss of their long-projecting axonal inputs to the striatum. Conventional cell therapy involves implanting dopaminergic neurons into the striatum; however, this strategy disregards the important systems-level implications of the native neuroanatomy. Pathway reconstruction strategies aim to address this limitation by replacing both neurons and axonal fibers in a manner that restores the anatomy – and hence circuit function – of the lost pathway. We have developed a reconstruction strategy whereby tissue-engineered nigrostriatal pathways (TE-NSPs) are pre-fabricated in vitro featuring a population of human stem cell-derived dopaminergic neurons and their long-projecting axonal tracts encased within a biocompatible tubular hydrogel. TE-NSPs may be implanted to directly replace the pathway, supplying both dopaminergic neurons to the nigra and providing axonal inputs to the striatum, thereby restoring crucial interconnectivity of the basal ganglia. In this proposal, we will answer a fundamental and neglected question in cell therapy for PD by characterizing whether pathway reconstruction with the TE-NSPs enables improved restoration of motor function compared to conventional striatal grafts in a rat model of PD. Our overarching hypothesis is that TE-NSPs will lead to more robust motor recovery than striatal grafts through a mechanism involving the reestablishment of physiological innervation and striatal dopamine regulation patterns more closely matching those of native basal ganglia. This hypothesis will be tested over three Aims: (1) Establish the ability of TE-NSPs to reconstruct basal ganglia circuitry via axonal-dendritic synaptic integration; (2) Demonstrate real-time efficacy of TE-NSPs in restoring nigrostriatal functionality; (3) Assess the influence of TE-NSP activity on motor recovery. TE-NSP mechanisms and efficacy will be compared to hydrogel-encased nigral or striatal grafts, acellular hydrogel implants, as well as non-implant and non-lesioned animals out to 24 weeks post-implantation. Motor function will be evaluated with rotational, forelimb asymmetry and adhesive removal tests. Innervation and connectivity patterns will be assessed with immunohistochemistry and monosynaptic rabies tracing, while ex vivo and in vivo voltammetry and [18F]F-DOPA positron emission tomography will be used to analyze real-time dopamine release and uptake in the striatum. We will also employ chemogenetics to silence neural activity in TE-NSPs to test the effects on motor function. Overall, TE-NSPs address a crucial gap in clinical treatment by providing a means to directly replace the nigrostriatal pathway, which may yield significant benefits over other methods by providing properly-regulated dopamine in the striatum as characteristic of integrated basal ganglia circuitry. These studies will further the long-term goal of advancing TE-NSPs as a Tissue Engineered Medical Product to mitigate the neuronal-axonal loss underlying the motor symptoms in patients afflicted by PD.

抽象的 帕金森病 (PD) 是一种进行性神经退行性疾病，影响全球 1000 万人。 其运动症状是由于黑质部多巴胺能神经元的选择性变性所致 致密体，导致其对纹状体的长投射轴突输入的损失。 涉及将多巴胺能神经元植入纹状体；然而，这种策略忽视了重要的因素。 天然神经解剖学的系统级影响旨在解决这个问题。 通过以恢复解剖结构的方式替换神经元和轴突纤维来克服限制 - 因此 我们开发了一种组织工程重建策略。 黑质纹状体通路 (TE-NSP) 是在体外预制的，具有源自人类干细胞的群体 多巴胺能神经元及其长突出的轴突束包裹在生物相容性管状水凝胶内。 可以植入 TE-NSP 来直接替代该通路，为黑质提供两个多巴胺能神经元 并向纹状体提供轴突输入，恢复基底神经节的重要互连性。 在这个提案中，我们将通过表征来回答 PD 细胞治疗中一个基本且被忽视的问题 与相比，TE-NSP 的通路重建是否能够改善运动功能的恢复 我们的总体假设是 TE-NSP 会导致更多的 PD 大鼠模型移植。 通过涉及生理学重建的机制，比纹状体移植物具有更强的运动恢复能力 神经支配和纹状体多巴胺调节模式与本地基底神经节更加匹配。 假设将通过三个目标进行检验：（1）建立 TE-NSP 重建基底神经节的能力 通过轴突-树突突触整合的电路；(2) 展示 TE-NSP 在恢复中的实时功效； (3)评估TE-NSP活性对运动恢复机制的影响。 并将功效与水凝胶包裹的黑质或纹状体移植物、无细胞水凝胶植入物以及 植入后 24 周内将评估非植入和未病变的动物的运动功能。 将进行旋转、前肢不对称和粘合剂去除测试。 通过免疫组织化学和单突触狂犬病追踪以及离体和体内伏安法进行评估 [18F]F-DOPA正电子发射断层扫描将用于分析实时多巴胺释放和 我们还将利用化学遗传学来抑制 TE-NSP 中的神经活动，以测试 总体而言，TE-NSP 通过提供一种方法来解决临床治疗中的一个关键差距。 直接取代黑质纹状体通路，这可能比其他方法产生显着的好处，因为 纹状体中多巴胺的适当调节是整合基底神经节电路的特征。 研究将进一步推进 TE-NSP 作为组织工程医疗产品的长期目标 减轻帕金森病患者运动症状背后的神经元轴突损失。